Skip to main content


Subcutaneous Implantable Defibrillator

play icon
EMBLEM S-ICD provides Protection Without Touching the Heart
EMBLEM S-ICD Protects Against Sudden Cardiac Arrest
EMBLEM MRI S-ICD System Animation
EMBLEM MRI Subcutaneous Implantable Defibrillator (S-ICD System)
EMBLEM MRI S-ICD System Protects Against Sudden Cardiac Arrest

The Only Device of its Kind

The EMBLEM MRI S-ICD is the only subcutaneous implantable defibrillator system that provides protection from both sudden cardiac death and the risks and complications associated with transvenous leads.

Key Resources



Product Details

The EMBLEM MRI S-ICD system provides effective defibrillation without transvenous leads, offering a less invasive solution for patients at risk of sudden cardiac arrest.

  • Preserves the vasculature
  • Eliminates potential for vascular injury, transvenous lead insertion complications, lead-associated tricuspid regurgitation,  mechanically induced pro-arrhythmia, and transvenous lead failure and associated extraction risk
  • Remains outside the sternum, never touching the heart
EMBLEM MRI S-ICD Pulse Generator Mechanical Specifications
Model Number A219
Size (W x H x D) 83.1 x 69.1 x 12.7 mm
Mass 130 g
Volume 59.5 cc (cm³)
Projected Longevity 8.7 years*
Battery Chemistry Boston Scientific Li/MnO2
Warranty 6 years**
Remote Patient Monitoring Capability Enabled for use with LATITUDE™ NXT remote patient management

*van der Stuijt W, Williams JL, Brisben AJ, et al. Real world battery longevity of the subcutaneous implantable cardioverter-defibrillator (S-ICD). European Heart Journal. 2023;44(Supplement_2)doi:10.1093/eurheartj/ehad655.684.

**For full warranty terms and conditions go to


Real World Evidence - Battery Longevity1

 Emblem S-ICD longevity has been clinically shown, based on real world evidence and data collected from 32,678 implanted S-ICD devices, to last 8.7 years...with all features turned on.

Click here to access the ESC Abstract on real world battery longevity. 

Clinical Information

The 2017 Guidelines by the American Heart Association (AHA), American College of Cardiology (ACC), and Heart Rhythm Society (HRS) include recommended use of the S-ICD for ICD indicated patients with2:



High Infection Risk

~75% of ICD Indicated Patients with ≥1 Comorbidities Associated with Device Infection.3, 4, 5

High infection risk chart

Inadequate Venous Access


Up to 61% of patients may have venous stenosis following initial device implantation.6

No Pacing Indication

% of VR and DR ICD Patients Under 75 with No Pacing Indication at Implant.

No pacing indication chart

Dr. Reinoud Knops Discusses the PRAETORIAN Trial at HRS in 2020
PRAETORIAN is the first prospective randomized head-to-head clinical trial confirming that the S-ICD can be the preferred therapy choice over the TV-ICD for protection from sudden cardiac arrest.9
Clinical Information image

Ordering Information

Model Number Description
A219 EMBLEM MRI S-ICD Pulse Generator
3501 EMBLEM S-ICD Electrode
4711 EMBLEM S-ICD Electrode Insertion Tool
3200 EMBLEM S-ICD Programmer


Rhythm Management Reimbursement Resources

Training & Education

Explore continuing education courses, best practices modules and other training and resources for S-ICD.


why sicd

Why S-ICD?

See how S-ICD helps protect patients at risk for sudden cardiac death while also eliminating the risk of TV-ICD lead complications.

Implant Procedure

Implant Procedure

Learn about advancements in the S-ICD implant procedure, including the 2-incision and intermuscular implant techniques.

Clinical Data

Clinical Data

Explore clinical outcomes and learn about the first prospective, randomized, non-inferiority clinical trial comparing S-ICD to TV-ICD.



1. van der Stuijt W, Williams JL, Brisben AJ, et al. Real world battery longevity of the subcutaneous implantable cardioverter-defibrillator (S-ICD). European Heart Journal. 2023;44(Supplement_2)doi:10.1093/eurheartj/ehad655.684.

2. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in J Am Coll Cardiol. 2018 Oct 2;72(14):1760]. J Am Coll Cardiol. 2018;72(14):e91-e220.

3. Polyzos, KA, Konstantelias, AA, and Falagas, ME, Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace, 2015. 17(5): p. 767-777. 

4. Greenspon, AJ, Patel, JD, Lau, E, et al., 16-Year Trends in the Infection Burden for Pacemakers and Implantable Cardioverter-Defibrillators in the United States. Journal of the American College of Cardiology, 2011. 58(10): p. 1001-1006. 

5. Friedman, DJ, Parzynski, CS, Varosy, PD, et al., Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. JAMA Cardiol, 2016. 1(8): p. 900-911.

6. Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction [published correction appears in Heart Rhythm. 2021 Oct;18(10):1814]. Heart Rhythm. 2017;14(12):e503-e551.

7. Gasparini M, Lunati MG, Proclemer A, et al. Long Detection Programming in Single-Chamber Defibrillators Reduces Unnecessary Therapies and Mortality: The ADVANCE III Trial. JACC Clin Electrophysiol. 2017;3(11):1275-1282.

8. Data on VR devices from LATITUDE Boston Scientific data on file.

9. Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al. Subcutaneous or Transvenous Defibrillator Therapy. N Engl J Med. 2020;383(6):526-536.